Intellia Therapeutics, Inc. (NTLA)
NASDAQ: NTLA · Real-Time Price · USD
12.61
+1.01 (8.71%)
Aug 19, 2026, 9:57 AM EDT - Market open
Intellia Therapeutics Cash Flow Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Operating Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | -399.98 | -412.69 | -519.02 | -481.19 | -474.19 | -267.89 |
Depreciation & Amortization | 15.24 | 15.92 | 10.29 | 8.98 | 7.57 | 6.89 |
Loss (Gain) From Sale of Assets | 0.68 | 0.53 | -0.08 | 0.07 | -0.16 | - |
Asset Writedown & Restructuring Costs | - | - | - | - | 55.99 | - |
Loss (Gain) From Sale of Investments | -2.37 | -4.96 | -6.22 | -19.27 | 15.41 | 10.54 |
Loss (Gain) on Equity Investments | - | - | - | 15.63 | 11.08 | 1.33 |
Stock-Based Compensation | 67.9 | 80.22 | 154.27 | 134.05 | 91.4 | 47.01 |
Other Operating Activities | - | - | - | 0.1 | 13.49 | - |
Change in Accounts Receivable | 4.03 | -0.95 | 27.94 | -32.69 | -1.74 | 0.1 |
Change in Accounts Payable | 1.91 | 5.99 | 6.8 | 2.52 | -4.58 | 0.53 |
Change in Unearned Revenue | -26.18 | -28.11 | -22.08 | -2.78 | -63.46 | -31.36 |
Change in Other Net Operating Assets | -7.88 | -50.68 | -0.79 | -19.51 | 15.91 | 7.82 |
Operating Cash Flow | -346.64 | -394.74 | -348.88 | -394.09 | -333.29 | -225.03 |
Operating Cash Flow Growth | - | - | - | - | - | - |
Investing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Capital Expenditures | -2.04 | -1.13 | -5.78 | -13.99 | -13.56 | -12.76 |
Sale of Property, Plant & Equipment | 0.09 | - | - | - | 0.15 | - |
Sale (Purchase) of Intangibles | - | - | - | - | -44.83 | - |
Investment in Securities | -46.52 | 229.16 | 131.35 | -17.36 | 218.55 | -538.02 |
Investing Cash Flow | -48.47 | 228.03 | 125.57 | -31.35 | 160.31 | -550.78 |
Financing Activities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Issuance of Common Stock | 346.52 | 131.49 | 185.75 | 130.32 | 582.96 | 736.69 |
Financing Cash Flow | 346.52 | 131.49 | 185.75 | 130.32 | 582.96 | 736.69 |
Net Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Cash Flow | -48.59 | -35.22 | -37.57 | -295.11 | 409.98 | -39.12 |
Free Cash Flow
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -348.69 | -395.87 | -354.66 | -408.07 | -346.85 | -237.79 |
Free Cash Flow Growth | - | - | - | - | - | - |
Free Cash Flow Margin | -585.97% | -584.99% | -612.78% | -1124.94% | -665.46% | -719.41% |
Free Cash Flow Per Share | -2.92 | -3.65 | -3.59 | -4.60 | -4.51 | -3.35 |
Levered Free Cash Flow | -249.83 | -233.29 | -133.38 | -268.21 | -256.18 | -69.57 |
Unlevered Free Cash Flow | -249.83 | -233.29 | -133.38 | -268.21 | -256.18 | -69.57 |